Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2001

View Archived Issues

Antisense oligonucleotide targeting PTP1B effective in animal models of diabetes, insulin resistance

Further results for NN-2211 continue to support its potential in type 2 diabetes

Dual-acting PPARgamma/PPARalpha agonist NNC-61-0029/(-)-DRF-2725: pharmacology and clinical PK

Adolor's opioid narcotic antagonist completes phase II trials for two indications

Crucell and Vaxin to jointly develop new noninvasive antiviral vaccines

BIBN-4096BS is a functionally selective CGRP receptor antagonist with potential in migraine Rx

AGY Therapeutics enters several alliances to identify drug targets for CNS diseases and obesity

Prophylaxis of refractory migraine with levetiracetam discussed at IHC 2001

ISTA completes enrollment in phase III study of Vitrase

TLK-286 enters phase II trial for non-small cell lung cancer

Pharmacological profile of a new ACAT inhibitor: R-755

Novirio establishes marketing agreement for LdT with Sumitomo

Phase III clinical trials of CV Therapeutics' CVT-510 commence

Matrix commences new phase II IntraDose study for primary liver cancer

Potential of topiramate for diabetes explored using animal models

Tetrahydroisoquinolines particularly useful in ADHD according to DuPont

New inhibitors of PDGF receptor autophosphorylation designed at JT

Newest factor Xa inhibitors and use in thromboembolic disorders reported by DuPont

COX-2-selective antiinflammatory, antiphlogistic and analgesic series claimed by Theramex

Mode of action of Oxigene's CA4P supported by preclinical data

Novel antiherpesvirus agents in the GSK pipeline

MacroChem completes phase III trial of Topiglan for treatment of ED

Adjunctive therapy with tizanidine for migraine prophylaxis

Allergan and Inspire collaborate on development of two ophthalmic products for dry eye

FDA grants fast track designation for irofulven in pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...